CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Darunavir/cobicistat

Last Updated: May 22, 2014
Result type: Reports
Project Number: SR0381-000
Product Line: Reimbursement Review

Generic Name: Darunavir/cobicistat

Brand Name: Prezcobix

Manufacturer: Janssen Inc.

Indications: HIV Infection

Submission Type: Pre-NOC

Project Status: Complete

Date Recommendation Issued: March 18, 2015

Recommendation Type: List with criteria/condition